| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Tricor Receives FDA Approval For Very High Triglycerides ABBOTT PARK, IL -- February 12, 1998 -- The United States Food and Drug Administration has granted marketing clearance to Abbott Laboratories and Groupe Fournier’s Tricor(TM), a micronized form of the drug fenofibrate, for patients with very high triglyceride levels. Fenofibrate is sold in 77 countries worldwide under the primary brand names Lipanthyl(R) and Lipidil(R). Abbott will market Tricor in the United States under a 1997 licensing agreement with the drug's developer, Groupe Fournier. In the U.S., Tricor is indicated as an adjunct to diet for the treatment of adults with very high serum triglyceride levels, specifically Types IV and V hyperlipidemia, who are not appropriately controlled by diet alone and are at risk of pancreatitis. Tricor should not be used in patients with liver, gall bladder or severe kidney disease, or in patients who are allergic to the drug.
|